FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer

  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 8 November 2020
ct scan
measurable disease
kidney function tests
neutrophil count
folfox regimen
adenocarcinoma of colon


The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of progression-free survival to conventional chemotherapy with the FOLFOX regimen as first-line treatment of chemo-naive metastatic colorectal cancer patients.

A second primary aim is to evaluate the response rate, safety and tolerability of the chemotherapy of FOLFOXIRI regimen in this patient population.

Patients will be randomized to two therapy groups:

Experimental arm A: Chemotherapy with FOLFOXIRI Standard arm B: Chemotherapy with FOLFOX


Survival of patients with metastatic colorectal cancer is correlated with the proportion of patients who receive all the three active drugs , but not with the proportion of patients who receive any second-line therapy. A superior efficacy in PFS,ORR and OS of FOLFOXIRI has been reported with acceptable toxicity. Moreover,evidence suggests that continuous dosing metronomic chemotherapy may be more efficacious than interval-chemotherapy.

Therefore, a way to improve the outcome of metastatic colorectal cancer patients could be to administer a maintenance first-line regimen containing the three active agents.

Condition Metastatic Colorectal Cancer
Clinical Study IdentifierNCT02128425
SponsorSun Yat-sen University
Last Modified on8 November 2020


Yes No Not Sure

Inclusion Criteria

Signed informed consent obtained before any study specific procedures. -Subjects must be able to understand and willing to sign a written informed consent
Male or female subjects 18 years 75 years of age
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2.(ECOG PS 0-2 for18 years 65 years of age ECOG PS 0-1 for 65 years of age)
Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded
There must be documentation by PET/CT scan, CT scan, MRI, or intraoperative palpation (at the time of resection of the primary colorectal tumor, if applicable) that the patient has evidence of metastases (Histologic confirmation of metastasis is not required.)
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria measured within 4 weeks prior to registration
No previous chemotherapy or target therapy for metastatic disease (adjuvant chemotherapy for non-metastatic disease is allowed if terminated more than 6 months ago)
In case of previous radiotherapy, at least one measurable lesion should be located outside the irradiated field
Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment
Leukocytes 3.0 x109/ L, absolute neutrophil count (ANC) 1.5 x109/ L, platelet count 100 x109/ L, hemoglobin (Hb) 9g/ dL
Total bilirubin 1.5 x the upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 5 x ULN
Alkaline phosphatase limit 5x ULN
Amylase and lipase 1.5 x the ULN
Serum creatinine 1.5 x the ULN
Calculated creatinine clearance or 24 hour creatinine clearance 50 mL/ min

Exclusion Criteria

Previous palliative chemotherapy for metastatic diseaseprevious adjuvant chemotherapy including irinotecan or oxaliplatin within 6 months before random assignment
Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization
Life expectancy > 12 weeks
Extended field radiotherapy within 4 weeks or limited field radiotherapy within 2 weeks prior to randomization. Subjects must have recovered from all therapy-related toxicities
Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks before start of study medication
Congestive heart failure New York Heart Association (NYHA) class 2
Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment or a history of ventricular arrhythmia
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication
Any evidence of active infection
History of interstitial pneumonitis or pulmonary fibrosis
Pregnancy or lactation at the time of study entry
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Any illness or medical conditions that are unstable or could jeopardize the safety of the subjects and his/her compliance in the study
Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea
Subjects with known allergy to the study drugs or to any of its excipients
Current or recent (within 4 weeks prior to starting study treatment) treatment of another investigational drug or participation in another investigational study
Continuous use of immunosuppressive agents (except the use of corticosteroids as anti-emetic prophylaxis/treatment)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note